GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advanced Proteome Therapeutics Corp (TSXV:APC.H) » Definitions » EPS (Diluted)

Advanced Proteome Therapeutics (TSXV:APC.H) EPS (Diluted) : C$-0.09 (TTM As of Apr. 2023)


View and export this data going back to 1989. Start your Free Trial

What is Advanced Proteome Therapeutics EPS (Diluted)?

Advanced Proteome Therapeutics's Earnings per Share (Diluted) for the three months ended in Apr. 2023 was C$-0.05. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2023 was C$-0.09.

Advanced Proteome Therapeutics's EPS (Basic) for the three months ended in Apr. 2023 was C$-0.05. Its EPS (Basic) for the trailing twelve months (TTM) ended in Apr. 2023 was C$-0.09.

Advanced Proteome Therapeutics's EPS without NRI for the three months ended in Apr. 2023 was C$-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Apr. 2023 was C$-0.05.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Advanced Proteome Therapeutics EPS (Diluted) Historical Data

The historical data trend for Advanced Proteome Therapeutics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Proteome Therapeutics EPS (Diluted) Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.07 -0.03 -0.03 -0.08 0.01

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.05

Competitive Comparison of Advanced Proteome Therapeutics's EPS (Diluted)

For the Biotechnology subindustry, Advanced Proteome Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Proteome Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advanced Proteome Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Advanced Proteome Therapeutics's PE Ratio falls into.



Advanced Proteome Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Advanced Proteome Therapeutics's Diluted EPS for the fiscal year that ended in Jul. 2022 is calculated as

Diluted EPS (A: Jul. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(0.983-0)/39.088
=0.03

Advanced Proteome Therapeutics's Diluted EPS for the quarter that ended in Apr. 2023 is calculated as

Diluted EPS (Q: Apr. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1.993-0)/40.711
=-0.05

EPS (Diluted) for the trailing twelve months (TTM) ended in Apr. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advanced Proteome Therapeutics  (TSXV:APC.H) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Advanced Proteome Therapeutics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Advanced Proteome Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Proteome Therapeutics (TSXV:APC.H) Business Description

Traded in Other Exchanges
Address
8337 Eastlake Drive, Suite 104, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.

Advanced Proteome Therapeutics (TSXV:APC.H) Headlines

No Headlines